← Leaderboards
Matthew S Davids
Dana-Farber Cancer Inst
$2,319,476
Attributed
$2,319,476
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $564.1K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,319,476 · 2
By mechanism
R01$1,603,351 · 1
P01$716,125 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Lili Wang$5,880,767
- Anthony G Letai$22,380,537
- Svitlana Tyekucheva$2,897,038
- Steven P. Balk$19,509,335
- Ursula Anne Matulonis$3,602,637
Others in their field
Other Emerging Leaders on “Design”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- John E West · University Of Texas At Austin$113,883,001
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Kevin Urdahl · Seattle Children'S Hospital$72,239,698
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
Research focus
DesignStandard Of CareClinical TrialsPatient-Focused OutcomesHigh RiskChronic Lymphocytic LeukemiaSamplingFutureGenomeEventFoundationsBone MarrowBone Marrow BiopsyGeneticEarly DiagnosisAwardEnsureBiobankBiologyDissectionCollectionBiopsyCellsCell Free Dna
Grant awards (9)
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia$403,340
R01 · FY2025 · CA · contact PI
Biospecimens$145,685
P01 · FY2025 · CA · contact PI
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia$383,236
R01 · FY2024 · CA · contact PI
Biospecimens$135,526
P01 · FY2024 · CA · contact PI
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia$395,400
R01 · FY2023 · CA · contact PI
Biospecimens$142,763
P01 · FY2023 · CA · contact PI
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia$421,375
R01 · FY2022 · CA · contact PI
Biospecimens$142,733
P01 · FY2022 · CA · contact PI
Biospecimens$149,418
P01 · FY2021 · CA · contact PI